相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
Retrospective Studyof 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data
Selin Carkaci et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry
Jason A. Zell et al.
BREAST CANCER RESEARCH (2009)
Prognostic significance of HER-2 status in women with inflammatory breast cancer
Shaheenah Dawood et al.
CANCER (2008)
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
Ian J. Bristol et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings
Wei T. Yang et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann et al.
ANNALS OF ONCOLOGY (2007)
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer
N. Cabioglu et al.
ANNALS OF ONCOLOGY (2007)
Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer
Steven A. Limentani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy - Ten-year results from the French Adjuvant Study Group GETS 02 Trial
Corinne Veyret et al.
CANCER (2006)
Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: A systematic review
Theodore Kim et al.
CLINICAL BREAST CANCER (2006)
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting
James L. Khatcheressian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy
Sabin B. Motwani et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype
Dang M. Nguyen et al.
CLINICAL CANCER RESEARCH (2006)
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer
J Hurley et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast
CG Kleer et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute
KW Hance et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Evolving role of positron emission tomography in breast cancer imaging
WB Eubank et al.
SEMINARS IN NUCLEAR MEDICINE (2005)
18F-2-fluoro-2-deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer
JJM van der Hoeven et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
High incidence of HER-2 positivity in inflammatory breast cancer
M Parton et al.
BREAST (2004)
Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally, advanced breast cancer
T Shenkier et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2004)
p53 expression as a prognostic marker in inflammatory breast cancer
AM Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2004)
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
JR Bellon et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2004)
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification
I Van der Auwera et al.
CLINICAL CANCER RESEARCH (2004)
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemothermpy
YC Cheng et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
JA Low et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Ten-year outcome after combined modality therapy for inflammatory breast cancer
EER Harris et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
HJ Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The role of 18F-FDG-PET in the local/regional evaluation of women with breast cancer
DN Danforth et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Inflammatory breast carcinoma:: Mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases
I Günhan-Bilgen et al.
RADIOLOGY (2002)
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy
G Vlastos et al.
AMERICAN JOURNAL OF SURGERY (2000)
Esthetic reconstruction after mastectomy for inflammatory breast cancer: Is it worthwhile?
PL Chin et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2000)
分享论文
